☆ 4.6 Article

Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc

BLOOD ADVANCES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant

Jeffrey J. Bednarski et al.

Summary: In this study, memory-like NK cells (ML NK cells) were used to treat relapsed pediatric and young adult patients with AML after HCT. The results showed that ML NK cells can persist and exhibit potent anti-leukemic activity in a compatible post-HCT immune environment. The combination of DLI and ML NK cells provides a novel immunotherapy platform for relapsed AML.

BLOOD (2022)

添加到收藏夹

Article Cell Biology

Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia

Melissa M. Berrien-Elliott et al.

Summary: In a clinical trial for relapsed/refractory acute myeloid leukemia (AML), same-donor memory-like (ML) NK cell therapy supported by N-803 successfully augmented reduced-intensity conditioning (RIC) haploidentical hematopoietic cell transplantation (HCT). Donor ML NK cells had unique phenotypic and transcriptional profiles and exhibited enhanced ex vivo function compared to conventional NK cells.

SCIENCE TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Oncology

CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells

Julie O'Neal et al.

Summary: The study suggests that CAR-T therapy targeting CS1 could be an effective treatment for multiple myeloma patients, and deleting CS1 in clinical production did not provide additional benefits.

LEUKEMIA (2022)

添加到收藏夹

Review Medicine, General & Internal

Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment

Gloria Delfanti et al.

Summary: Invariant Natural Killer T (iNKT) cells are a type of lymphocytes that can combat solid and hematological malignancies. They have unique functional features and are attractive for cell immunotherapy. iNKT cells can directly kill cancer cells and suppress immunosuppressive cells in the tumor microenvironment. Moreover, they can be transplanted across MHC barriers without causing alloreaction because of the identical CD1d molecules in all individuals.

FRONTIERS IN MEDICINE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity

Miriam Y. Kim et al.

Summary: A study has found that a long-acting form of recombinant human interleukin-7 can enhance the efficacy of chimeric antigen receptor (CAR) T cell therapy, promoting cell proliferation, persistence, and cytotoxicity, resulting in long-term tumor-free survival.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Hematology

A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions

Sojeong Kim et al.

Summary: This study investigated the effects of long-acting recombinant human interleukin-7 (hIL-7-hyFc) in healthy adults. The results showed that hIL-7-hyFc can sustainably increase the numbers of CD8+ and CD4+ T cells without altering the quantity and quality of regulatory T cells (Tregs).

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

Allogeneic natural killer cell therapy

Melissa M Berrien-Elliott et al.

BLOOD (2022)

添加到收藏夹

Article Oncology

Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies

Stefanie R. Bailey et al.

Summary: Blocking IFN gamma in CAR T cells does not impair their cytotoxicity against hematologic tumor cells and paradoxically enhances their proliferation and reduces macrophage-mediated cytokines and chemokines associated with CRS. These findings suggest that IFN gamma blockade may improve CAR T-cell function while reducing treatment-related toxicity in hematologic malignancies.

BLOOD CANCER DISCOVERY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma

Renee Poels et al.

Summary: iNKT cells armed with CD38 and BCMA-CARs effectively eliminate MM cells without compromising their TCR-mediated cytotoxicity. These CAR iNKT cells show promising therapeutic potential with minimal impact on normal hematopoietic cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming

Federico Simonetta et al.

Summary: The study assessed the antitumor effects of allogeneic CAR iNKT cells, demonstrating their ability to induce tumor-specific immunity across major MHC barriers and elicit potent antitumor responses from host CD8 T cells. This suggests that the use of off-the-shelf allogeneic CAR iNKT cells could address significant unmet needs in the clinic.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Hematology

B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis

Nico Gagelmann et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Enli Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, Research & Experimental

hhIL-7-hyFc, A Long-Acting IL-7, Increased Absolute Lymphocyte Count in Healthy Subjects

Sang Won Lee et al.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)

添加到收藏夹

Article Hematology

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Margery Gang et al.

BLOOD (2020)

添加到收藏夹

Review Oncology

Macrophage, the potential key mediator in CAR-T related CRS

Zhaonian Hao et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

Andras Heczey et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Oncology

Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Melissa M. Berrien-Elliott et al.

CANCER DISCOVERY (2020)

添加到收藏夹

Article Immunology

IL-7 During Antigenic Stimulation Using Allogeneic Dendritic Cells Promotes Expansion of CD45RA-CD62L+CD4+ Invariant NKT Cells With Th-2 Biased Cytokine Production Profile

Abel Trujillo-Ocampo et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma

Adam D. Cohen et al.

JOURNAL OF CLINICAL INVESTIGATION (2019)

添加到收藏夹

Article Medicine, General & Internal

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Noopur Raje et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Multidisciplinary Sciences

leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

Jie Xu et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

添加到收藏夹

Article Oncology

NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma

Xin Xu et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Review Hematology

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

Jennifer N. Brudno et al.

BLOOD REVIEWS (2019)

添加到收藏夹

Article Hematology

Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies

Mathew L. Cooper et al.

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells

Kevin M. Friedman et al.

HUMAN GENE THERAPY (2018)

添加到收藏夹

Article Oncology

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Jennifer N. Brudno et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Immunology

IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy

Ho Ngai et al.

JOURNAL OF IMMUNOLOGY (2018)

添加到收藏夹

Article Oncology

Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting

Antonia Rotolo et al.

CANCER CELL (2018)

添加到收藏夹

Article Oncology

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Wan-Hong Zhao et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

添加到收藏夹

Article Immunology

Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation

Melissa Mavers et al.

Frontiers in Immunology (2017)

添加到收藏夹

Article Hematology

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

Syed Abbas Ali et al.

BLOOD (2016)

添加到收藏夹

Article Medicine, Research & Experimental

CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo

Gengwen Tian et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

添加到收藏夹

Article Oncology

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

S. K. Kumar et al.

LEUKEMIA (2014)

添加到收藏夹

Article Hematology

Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome

Alexander Astrakhan et al.

BLOOD (2012)

添加到收藏夹

Article Hematology

Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival

Marie-Therese Rubio et al.

BLOOD (2012)

添加到收藏夹

Article Hematology

Regulation of multiple myeloma survival and progression by CD1d

Emmanouil Spanoudakis et al.

BLOOD (2009)

添加到收藏夹

Article Immunology

Innate-like effector differentiation of human invariant NKT cells driven by IL-7

Claudia de Lalla et al.

JOURNAL OF IMMUNOLOGY (2008)

添加到收藏夹

Article Immunology

Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation

MP Rettig et al.

JOURNAL OF IMMUNOLOGY (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.